Skip to main content

Advertisement

Log in

Inhibition of the Androgen Receptor by Antiandrogens in Spinobulbar Muscle Atrophy

  • Published:
Journal of Molecular Neuroscience Aims and scope Submit manuscript

Abstract

Spinal-bulbar muscle atrophy (SBMA) or also named Kennedy’s Disease is caused by a polyglutamine expansion (PolyQ) of the coding region of the androgen receptor (AR). The AR is a ligand-controlled transcription factor and member of the nuclear hormone receptor superfamily. The central characteristics of the SBMA pathogenicity are muscle weakness, the loss of motoneurons and the occurrence of AR-containing protein aggregates that are observed in spinal cord motoneurons and skeletal muscles induced by the AR-PolyQ expansion in the presence of androgens. The PolyQ triggers a misfolding in the AR-PolyQ and leads to protein aggregation in spinal cord motoneurons and muscle cells. The AR-PolyQ toxicity is activated by the AR ligand testosterone and dihydrotestosterone that activate the receptor and triggers nuclear toxicity by inducing AR nuclear translocation. In line with this, androgen treatment of SBMA patients worsened the SBMA symptoms. SBMA has been modeled in AR-overexpressing and AR-PolyQ-knock-in animals, but precisely how the PolyQ expansion leads to neurodegeneration is unclear. The androgen-induced toxicity and androgen-dependent nuclear accumulation of AR-PolyQ protein seems to be central to the pathogenesis. Therefore, the inhibition of the androgen-activated AR-PolyQ might be a therapeutic option. Here the use of AR antagonists for treatment option of SBMA will be reviewed and discussed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Abbreviations

AR:

Androgen Receptor

DHT:

Dihydrotestosterone

LHRH:

Luteinizing Hormone-Releasing Hormone

PolyQ:

Polyglutamine Expansion

SBMA:

Spinal-Bulbar Muscle Atrophy

References

  • Banno H, Katsuno M, Suzuki K, Tanaka F, Sobue G (2012) Pathogenesis and molecular targeted therapy of spinal and bulbar muscular atrophy (SBMA). Cell Tissue Res 1:313–320

    Article  Google Scholar 

  • Becker M, Martin E, Schneikert J, Krug HF, Cato AC (2000) Cytoplasmic localization and the choice of ligand determine aggregate formation by androgen receptor with amplified polyglutamine stretch. J Cell Biol 149(2):255–262

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Darrington RS, Butler R, Leigh PN, McPhaul MJ, Gallo JM (2002) Ligand-dependent aggregation of polyglutamine-expanded androgen receptor in neuronal cells. Neuroreport 13(16):2117–2120

    Article  CAS  PubMed  Google Scholar 

  • Dotzlaw H, Moehren U, Mink S, Cato AC, Iñiguez Lluhí JA, Baniahmad A (2002) The amino terminus of the human AR is target for corepressor action and antihormone agonism. Mol Endocrinol 16(4):661–673

    Article  CAS  PubMed  Google Scholar 

  • Dotzlaw H, Papaioannou M, Moehren U, Claessens F, Baniahmad A (2003) Agonist–antagonist induced coactivator and corepressor interplay on the human androgen receptor. Mol Cell Endocrinol 213(1):79–85

    Article  CAS  PubMed  Google Scholar 

  • Fernández-Rhodes LE, Kokkinis AD, White MJ, Watts CA, Auh S, Jeffries NO, Shrader JA, Lehky TJ, Li L, Ryder JE, Levy EW, Solomon BI, Harris-Love MO, La Pean A, Schindler AB, Chen C, Di Prospero NA, Fischbeck KH (2011) Efficacy and safety of dutasteride in patients with spinal and bulbar muscular atrophy: a randomised placebo-controlled trial. Lancet Neurol 10(2):140–147

    Article  PubMed  PubMed Central  Google Scholar 

  • Fousteris MA, Schubert U, Roell D, Roediger J, Bailis N, Nikolaropoulos SS, Baniahmad A, Giannis A (2010) 20-Aminosteroids as a novel class of selective and complete androgen receptor antagonists and inhibitors of prostate cancer cell growth. Bioorg Med Chem 18(19):6960–6969

    Article  CAS  PubMed  Google Scholar 

  • Giorgetti E, Rusmini P, Crippa V, Cristofani R, Boncoraglio A, Cicardi ME, Galbiati M, Poletti A (2015) Synergic prodegradative activity of Bicalutamide and trehalose on the mutant androgen receptor responsible for spinal and bulbar muscular atrophy. Hum Mol Genet 24(1):64–75

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Helsen C, Van den Broeck T, Voet A, Prekovic S, Van Poppel H, Joniau S, Claessens F (2014) Androgen receptor antagonists for prostate cancer therapy. Endocr Relat Cancer 21(4):T105–T118

    Article  CAS  PubMed  Google Scholar 

  • Hessenkemper W, Roediger J, Bartsch S, Houtsmuller AB, van Royen ME, Petersen I, Grimm M-O, Baniahmad A (2014) A natural androgen receptor antagonist induces cellular senescence in prostate cancer cells. Mol Endocrinol 28(11):1831–1840

    Article  PubMed  Google Scholar 

  • Hodgson MC, Astapova I, Hollenberg AN, Balk SP (2007) Activity of androgen receptor antagonist bicalutamide in prostate cancer cells is independent of NCoR and SMRT corepressors. Cancer Res 67(17):8388–8395

    Article  CAS  PubMed  Google Scholar 

  • Jochum T, Ritz ME, Schuster C, Funderburk SF, Jehle K, Schmitz K, Brinkmann F, Hirtz M, Moss D, Cato AC (2012) Toxic and non-toxic aggregates from the SBMA and normal forms of androgen receptor have distinct oligomeric structures. Biochim Biophys Acta 1822(6):1070–1078

    Article  CAS  PubMed  Google Scholar 

  • Johansen JA, Troxell-Smith SM, Yu Z, Mo K, Monks DA, Lieberman AP, Breedlove SM, Jordan CL (2011) Prenatal flutamide enhances survival in a myogenic mouse model of spinal bulbar muscular atrophy. Neurodegener Dis 8(1–2):25–34

    Article  CAS  PubMed  Google Scholar 

  • Katsuno M, Banno H, Suzuki K, Adachi H, Tanaka F, Sobue G (2010) Clinical features and molecular mechanisms of spinal and bulbar muscular atrophy (SBMA). Adv Exp Med Biol 685:64–74

    Article  CAS  PubMed  Google Scholar 

  • Katsuno M, Tanaka F, Adachi H, Banno H, Suzuki K, Watanabe H, Sobue G (2012) Pathogenesis and therapy of spinal and bulbar muscular atrophy (SBMA). Prog Neurobiol 99(3):246–256

    Article  CAS  PubMed  Google Scholar 

  • Kinirons P, Rouleau GA (2008) Administration of testosterone results in reversible deterioration in Kennedy’s disease. J Neurol Neurosurg Psychiatry 79(1):106–107

    Article  CAS  PubMed  Google Scholar 

  • Montie HL, Cho MS, Holder L, Liu Y, Tsvetkov AS, Finkbeiner S, Merry DE (2009) Cytoplasmic retention of polyglutamine-expanded androgen receptor ameliorates disease via autophagy in a mouse model of spinal and bulbar muscular atrophy. Hum Mol Genet 18(11):1937–1950

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Nedelsky NB, Pennuto M, Smith RB, Palazzolo I, Moore J, Nie Z, Neale G, Taylor JP (2010) Native functions of the androgen receptor are essential to pathogenesis in a Drosophila model of spinobulbar muscular atrophy. Neuron 67(6):936–952

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Orr CR, Montie HL, Liu Y, Bolzoni E, Jenkins SC, Wilson EM, Joseph JD, McDonnell DP, Merry DE (2010) An interdomain interaction of the androgen receptor is required for its aggregation and toxicity in spinal and bulbar muscular atrophy. J Biol Chem 285(46):35567–35577

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Papaioannou M, Schleich S, Prade I, Degen S, Roell D, Schubert U, Tanner T, Claessens F, Matusch R, Baniahmad A (2009) The natural compound atraric acid is an antagonist of the human androgen receptor inhibiting cellular invasiveness and prostate cancer cell growth. J Cell Mol Med 13(8B):2210–2223

    Article  PubMed  Google Scholar 

  • Parodi S, Pennuto M (2011) Neurotoxic effects of androgens in spinal and bulbar muscular atrophy. Front Neuroendocrinol 32(4):416–425

    Article  CAS  PubMed  Google Scholar 

  • Perner S, Cronauer MV, Schrader AJ, Klocker H, Culig Z, Baniahmad A (2015) Adaptive responses of androgen receptor signaling in castration-resistant prostate cancer. Oncotarget, in press.

  • Renier KJ, Troxell-Smith SM, Johansen JA, Katsuno M, Adachi H, Sobue G, Chua JP, Sun Kim H, Lieberman AP, Breedlove SM, Jordan CL (2014) Antiandrogen flutamide protects male mice from androgen-dependent toxicity in three models of spinal bulbar muscular atrophy. Endocrinology 155(7):2624–2634

    Article  PubMed  PubMed Central  Google Scholar 

  • Rocchi A, Pennuto M (2013) New routes to therapy for spinal and bulbar muscular atrophy. J Mol Neurosci 50(3):514–523

    Article  CAS  PubMed  Google Scholar 

  • Roell D, Baniahmad A (2011) The natural compounds atraric acid and N-butylbenzene-sulfonamide as antagonists of the human androgen receptor and inhibitors of prostate cancer cell growth. Mol Cell Endocrinol 332(1–2):1–8

    Article  CAS  PubMed  Google Scholar 

  • Rusmini P, Crippa V, Giorgetti E, Boncoraglio A, Cristofani R, Carra S, Poletti A (2013) Clearance of the mutant androgen receptor in motoneuronal models of spinal and bulbar muscular atrophy. Neurobiol Aging 34(11):2585–2603

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Shimohata T, Kimura T, Nishizawa M, Onodera O, Tsuji S (2004) Five year follow up of a patient with spinal and bulbar muscular atrophy treated with leuprorelin. J Neurol Neurosurg Psychiatry 75(8):1206–1207

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Simeoni S, Mancini MA, Stenoien DL, Marcelli M, Weigel NL, Zanisi M, Martini L, Poletti A (2000) Motoneuronal cell death is not correlated with aggregate formation of androgen receptors containing an elongated polyglutamine tract. Hum Mol Genet 9(1):133–144

    Article  CAS  PubMed  Google Scholar 

  • Stenoien DL, Cummings CJ, Adams HP, Mancini MG, Patel K, DeMartino GN, Marcelli M, Weigel NL, Mancini MA (1999) Polyglutamine-expanded androgen receptors form aggregates that sequester heat shock proteins, proteasome components and SRC-1, and are suppressed by the HDJ-2 chaperone. Hum Mol Genet 8(5):731–741

    Article  CAS  PubMed  Google Scholar 

  • Tan ME, Li J, Xu HE, Melcher K, Yong EL (2014) Androgen receptor: structure, role in prostate cancer and drug discovery. Acta Pharmacol Sin 1–21

  • Tanaka F, Katsuno M, Banno H, Suzuki K, Adachi H, Sobue G (2012) Current status of treatment of spinal and bulbar muscular atrophy. Neural Plast 2012:369284

    PubMed  PubMed Central  Google Scholar 

  • Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V, Wongvipat J, Smith-Jones PM, Yoo D, Kwon A, Wasielewska T, Welsbie D, Chen CD, Higano CS, Beer TM, Hung DT, Scher HI, Jung ME, Sawyers CL (2009) Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 324(5928):787–790

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Yoon HG, Wong J (2006) The corepressors silencing mediator of retinoid and thyroid hormone receptor corepressor are involved in agonist- and antagonist-regulated transcription by androgen receptor. Mol Endocrinol 20:1048–1060

    Article  CAS  PubMed  Google Scholar 

  • Yu Z, Dadgar N, Albertelli M, Gruis K, Jordan C, Robins DM, Lieberman AP (2006) Androgen-dependent pathology demonstrates myopathic contribution to the Kennedy disease phenotype in a mouse knock-in model. J Clin Invest 116(10):2663–2672

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgments

I am grateful to Mohsen Esmaeili for critically reading the manuscript.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Aria Baniahmad.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Baniahmad, A. Inhibition of the Androgen Receptor by Antiandrogens in Spinobulbar Muscle Atrophy. J Mol Neurosci 58, 343–347 (2016). https://doi.org/10.1007/s12031-015-0681-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12031-015-0681-8

Keywords

Navigation